درباره این اپیزود
The next frontier of medicine is focused on highly targeted drug therapies that could expand the possibilities of individualized patient care. Today, scientists are working on a particular type of molecule that could harness multiple capabilities and treat inflammatory and autoimmune diseases in ways never done before.
In this episode, co-hosts Dr. Raven Baxter and Dr. Ronald Gamble explore how the latest advancements in antibody engineering led to multispecific antibodies—powerhouse molecules that can do the jobs of multiple drugs in one. They learn all about what it takes to assemble these antibodies and the impact they could make on patients—with a patient.
Featured Guests:
– Emma Guttman, Chair of the Department of Dermatology, Icahn School of Medicine at Mount Sinai
– Amanda Lopez, Patient, Texas Ambassador for the National Eczema Association
– Laird Bloom, Senior Director of Biomedicine Design, Pfizer
– Thomas Wynn, Vice President of Discovery, Inflammation & Immunology, Pfizer
Dive into the episode here:
1:12 - A metaphor for multispecific antibodies
4:08 - How do multispecific antibodies work?
10:39 - The history behind multispecific antibodies
16:29 - How are multispecific antibody drugs are made?
22:58 - An eczema expert on the potential of multispecific antibodies
29:30 - Amanda Lopez's eczema story
40:14 - What's next, and closing thoughts
Season 5 of Science Will Win is created by Pfizer and hosted by Dr. Raven Baxter and Dr. Ronald Gamble. It’s produced by Acast Creative Studios.
Check out our social media platforms to take a deeper look into the labs and stories we discuss during the episodes: Instagram (@pfizerinc), TikTok (@pfizer)
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
